|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 19.12 USD | -2.99% |
|
-3.34% | -28.42% |
| 10-13 | ACADIA Pharmaceuticals Shares Fall After UBS Downgrade | MT |
| 10-13 | Top Midday Decliners | MT |
| Market Cap | 3.29B 2.93B 2.71B 2.47B 4.65B 313B 4.73B 32.61B 12.85B 163B 12.36B 12.1B 520B | P/E 2026 * |
31x | P/E 2027 * | 21.4x |
|---|---|---|---|---|---|
| Enterprise Value | 2.29B 2.04B 1.88B 1.71B 3.23B 217B 3.28B 22.62B 8.92B 113B 8.58B 8.39B 361B | EV / Sales 2026 * |
1.8x | EV / Sales 2027 * | 1.44x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ACAD | Delayed | |
CBOE
| ACAD | Real-time | |
|
Tradegate
| DR6 | Real-time | |
|
Mexican S.E.
| ACAD * | End-of-day quote | |
|
Deutsche Boerse AG
| DR6 | Delayed | |
|
Börse Stuttgart
| DR6 | Delayed | |
|
Boerse Muenchen
| DR6 | Real-time |
Last Transcript: Acadia Pharmaceuticals Inc.
| 1 day | -2.99% | ||
| 1 week | -3.34% | ||
| Current month | -5.11% | ||
| 1 month | -30.35% | ||
| 3 months | -25.31% | ||
| 6 months | -13.76% | ||
| Current year | -28.42% |
| 1 week | 18.39 |  | 19.88 |
| 1 month | 18.39 | | 27.43 |
| Current year | 18.39 | | 30.96 |
| 1 year | 18.39 | | 30.96 |
| 3 years | 13.4 | | 32.59 |
| 5 years | 12.24 | | 33.99 |
| 10 years | 12.24 | | 58.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Catherine Adams
CEO | Chief Executive Officer | 55 | 2024-09-19 |
Mark Schneyer
DFI | Director of Finance/CFO | 52 | 2021-09-09 |
Scott Cenci
CTO | Chief Tech/Sci/R&D Officer | - | 2025-08-03 |
| Director | Title | Age | Since |
|---|---|---|---|
Laura Brege
BRD | Director/Board Member | 68 | 2008-04-30 |
Stephen Biggar
CHM | Chairman | 55 | 2016-06-09 |
Edmund Harrigan
BRD | Director/Board Member | 73 | 2015-11-24 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/6/26 | Exercice | Chief Financial Officer | 42,876 | 0.0250% | ||
| 7/30/26 | Sell | Chief Technology Officer | -16,558 | 0.0097% | ||
| 5/29/26 | Exercice | Director | 41,529 | 0.0243% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.99% | -3.34% | -8.47% | -18.29% | 3.29B | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +9.98% | 22.5B | |
| Average | -1.79% | -0.65% | +40.12% | +83.06% | 37.57B | |
| Weighted average by Cap. | -2.20% | -0.52% | +43.78% | +95.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.27B 1.13B 1.05B 954M 1.8B 121B 1.83B 12.59B 4.96B 62.99B 4.77B 4.67B 201B | 1.43B 1.27B 1.18B 1.07B 2.02B 136B 2.05B 14.15B 5.58B 70.82B 5.37B 5.25B 226B |
| Net income | 108M 96.39M 89.15M 81.16M 153M 10.27B 155M 1.07B 422M 5.36B 406M 397M 17.08B | 162M 144M 133M 121M 228M 15.34B 232M 1.6B 630M 8B 606M 593M 25.49B |
| Net Debt | -1.01B -899M -831M -757M -1.43B -95.8B -1.45B -9.99B -3.94B -49.96B -3.79B -3.71B -159B | -1.24B -1.1B -1.02B -928M -1.75B -117B -1.78B -12.24B -4.83B -61.26B -4.64B -4.54B -195B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | US$19.12 | -2.99% | 1,672,256 |
| 26-10-15 | US$19.71 | +2.39% | 1,767,168 |
| 26-10-14 | US$19.25 | +3.38% | 1,642,771 |
| 26-10-13 | US$18.62 | -4.07% | 2,140,646 |
| 26-10-12 | US$19.41 | -1.87% | 1,184,727 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACAD Stock
Select your edition
All financial news and data tailored to specific country editions
